Researchers from many international institutions have teamed up to design a more effective drug for liver cancer therapy. Their compound may help improve survival rates and reduce adverse effects.
Hepatocellular carcinoma, or primary liver cancer, tends to grow and expand at a fast rate.
If it is not caught early, this means that people who have been diagnosed with it may not survive longer than 11 months.
Recent studies show that in the United States, hepatocellular carcinoma is the ninth leading cause of cancer-related deaths.
